1. Introduction
The nervous system is an intricate and highly specialized network of neurons. Neuronal differentiation involves complex reprogramming of gene expression. Alternative splicing of precursor mRNAs increases the complexity of transcriptomes and diversifies protein functions at the post-transcriptional level. Indeed, alternative splicing plays an important role in neuronal differentiation, axon guidance, synaptogenesis, synaptic transmission, and plasticity. Because the delicate structure and function of neurons make them particularly susceptible to dysregulation of splicing, aberrant expression or function of splicing factors may cause neuronal disorders. Therefore, it is important to improve our understanding of the mechanisms and physiological functions of alternative splicing regulation in neurons. Regulation of alternative splicing primarily involves the binding of regulatory factors to specific
2. Introduction to alternative splicing
Recent estimates have indicated that as many as 95% of human genes generate alternatively spliced mRNAs (Pan, et al., 2008; E. T. Wang, et al., 2008). Alternative splicing of precursor mRNAs (pre-mRNAs) may alter the coding sequence and hence change the function or stability of the encoded proteins. Moreover, alternative splicing may create pre-mature termination codons within the coding region due to frame shift, thereby inducing mRNA destruction via the nonsense-mediated decay pathway (Isken & Maquat, 2007; McGlincy & Smith, 2008; Moore & Proudfoot, 2009). Alterative splicing may also occur in the 3' untranslated region of a pre-mRNA and thus create or eliminate
Alternative splicing plays a critical role in many fundamental biological processes, such as cell differentiation and specification during development and specificity of function in diverse cell types (Keren, et al., 2010; Nilsen & Graveley, 2010). The nervous system also adopts alternative splicing for cell differentiation, morphogenesis, and even for formation of complex neuronal networks and delicate synapse formation/plasticity (Calarco, et al., 2009; Grabowski, 2011; Li, et al., 2007). An extreme case of alternative splicing is the gene encoding
Alternative splicing is primarily controlled by splicing regulatory factors that bind to
The repertoire of splicing factors is adjusted during neuronal differentiation and perhaps for functional specification of different neuronal cell types. For example, the switch in the expression of the polypyrimidine tract-binding protein (PTB) to its neuronal homolog, nPTB, may tune neuronal transcriptomes during differentiation (Coutinho-Mansfield, et al., 2007; Tang, et al., 2011). In addition to RNA-binding factors, altered abundance of basic splicing machinery components may also modulate splice site selection (Calarco, et al., 2011; Saltzman, et al., 2011). The survival of motor neuron (SMN) protein is a key factor for the assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs). SMN deficiency may reduce snRNP abundance and thus influence splicing. Defective Nova and/or SMN proteins are associated with disease (Robert B. Darnell, 2011; Lorson, et al., 2010; Lukong, et al., 2008; G. H. Park, et al., 2010). Therefore, to understand how defects of Nova and SMN induce pathological effects on neurons via misregulated splicing control is an interesting and important question. Therefore, a complete understanding of such diseases will require knowledge of how misregulated splicing control in Nova or SMN causes neuronal pathology.
We hereby discuss our current knowledge of Nova, PTB/nPTB, and SMN with respect to their splicing regulation mechanisms, physiological roles, and functions.
3. Nova
3.1. Nova proteins and expression
Nova was discovered as a target of the autoantibodies in cancer patients with paraneoplastic opsoclonus myoclonus ataxia, a type of rare paraneoplastic neurologic disease that causes motor disorders (Buckanovich, et al., 1993; R. B. Darnell & Posner, 2003; Yang, et al., 1998). The amino acid sequences of the two mammalian Nova proteins (1 and 2) are highly similar throughout their lengths, and both contain three heterogeneous nuclear RNP (hnRNP) K-homology (KH) RNA-binding domains (Buckanovich, et al., 1996; Yang, et al., 1998). In mice, Nova-1 expression is restricted in subcortical regions of developing and mature neurons, whereas Nova-2 is more broadly expressed in the central nervous system (Buckanovich, et al., 1993; Buckanovich, et al., 1996; Yang, et al., 1998). Moreover, Nova-1 and Nova-2 appear to be reciprocally expressed in the nervous system, i.e., the level of Nova-2 is generally low in regions where Nova-1 is abundant, which may reflect their distinct biological functions (Yang, et al., 1998). Nevertheless, Nova-1 and -2 primarily act as splicing regulatory factors and also play a role in alternative polyadenylation and mRNA trafficking in neuronal dendrites (Licatalosi, et al., 2008; Racca, et al., 2010).
3.2. RNA-binding specificity of Nova
The RNA-binding specificity of the Nova proteins has been examined by various methods. Initially, the results of
Next, ultraviolet cross-linking in conjunction with ribonucleoprotein immunoprecipitation (CLIP) was developed to identify
Moreover, the aforementioned CLIP analyses also revealed that the largest set of Nova tags is located within introns and even flanking alternative exons (Licatalosi, et al., 2008 which is consistent with the primary role of Nova proteins in regulating pre-mRNA splicing (see below). In addition, Nova tags are also found in protein-coding regions and 3' untranslated region of mRNAs. The results of HITS-CLIP experiments have confirmed the high frequency of potential Nova-binding elements in 3' untranslated regions, thus disclosing a role for Nova in alternative polyadenylation and mRNA transport regulation in brain (Licatalosi, et al., 2008; Racca, et al., 2010).
3.3. Alternative splicing regulated by Nova
Earlier studies have shown that two neuronal transcripts, encoding the inhibitory glycine receptor α2 (GlyRα2) and Nova-1 itself, contain the Nova-1-binding elements adjacent to the alternatively spliced exons and indeed bound to the Nova-1 protein (Buckanovich & Darnell, 1997). The role of Nova-1 in splicing regulation was first analyzed by genetic knockout of Nova-1 in mice (Jensen, et al., 2000); in those mice, selection of GlyRα2 exon 3A is diminished. Further experiments demonstrated that Nova-1 binds to three consecutive YCAY repeats in the intron upstream of exon 3A and thereby increases exon 3A inclusion. Alternative exon selection in another neuronal ionotropic receptor, GABAA Rγ2, is also impaired in Nova-1 null mice (Dredge & Darnell, 2003; Jensen, et al., 2000). Nova-1 was subsequently shown to promote GABAA Rγ2 exon 9 inclusion via a distal downstream intronic YCAY-rich splicing enhancer. Notably, the Nova-1 gene itself harbors five YCAY repeats in its exon 4 that are indeed essential for Nova-1 autoregulation (Dredge, et al., 2005). Inclusion of exon 4 in Nova-1 transcripts was increased in haploinsufficient Nova+/– mice. Accordingly, exon 4 inclusion in a Nova-1 splicing reporter was suppressed upon Nova-1 overexpression. In this case, Nova-1 acts via binding to the YCAY repeats in the alternative exon. Therefore, Nova can function either as a positive or negative splicing regulator via binding to intronic or exonic YCAY elements. Further study by swapping of Nova-1-binding sites between various splicing substrates of Nova-1 indicated that the action of Nova-1 is determined by the position of the Nova-binding elements (Dredge, et al., 2005). This positional effect has also been found in other splicing regulators (see below).
Through CLIP and exon junction arrays, a large number of the potential targets of Nova, including some previously defined targets, have been identified (Ule, et al., 2003). Alternative splicing of several candidates was indeed altered in Nova knockout mice, confirming that those transcripts undergo Nova-mediated splicing control. This systematic and genome-wide identification also indicted that Nova may coregulate a set of synaptic and axonal transcripts by controlling alternative splicing. Such coordinated control of alternative exon usage may perhaps provide a powerful means to rapidly modulate synaptic function in response to stimuli.
More recently, HITS-CLIP analysis established functional RNA binding maps of Nova (Licatalosi, et al., 2008). That analysis predicted ~600 differentially spliced exons in brain that are potentially targeted by Nova-2. The transcripts harboring some of the identified exons showed a severe splicing defect in the neocortex of Nova-2 null mice, where Nova-2 is exclusively expressed. However, minor effects were seen in the spinal cord, cerebellum, and midbrain perhaps owing to redundancy of Nova-1 and Nova-2 in these tissues (Licatalosi, et al., 2008). Other work has indicated that Nova proteins regulate alternative splicing across all members of the spectrin-ankyrin-protein 4.1-CASK scaffold complex and the Cav2.2 voltage-gated calcium channels and thereby may finely modulate synaptic function in a coordinated way (Licatalosi, et al., 2008; Ule, et al., 2005b). A genome-wide search in combination with gene ontology analysis revealed that Nova-2-regulated transcripts encode a group of synaptic proteins located at the cell membrane, most often at cell-cell junctions, and are implicated in synapse biogenesis and synaptic transmission. Therefore, Nova-1 and -2 may function analogously in regulating alternative splicing of pre-mRNAs encoded by functionally related genes in neurons.
3.4. Mechanisms of Nova-mediated splicing regulation
The interplay between Nova proteins and
Bioinformatic analysis of the Nova HITS-CLIP data using Bayesian networks has further provided a comprehensive view of alternative splicing coordinately regulated by Nova and cofactors (C. Zhang, et al., 2010). This analysis initially predicted more than 600 Nova-regulated alternative splicing events. Gene ontology classification supported the hypothesis that Nova may regulate a subgroup of functionally coherent genes involved in synaptic plasticity. This analysis also revealed that the avidity with which Nova binds YCAY clusters may modulate how Nova affects splicing. Moreover, Nova binding to multiple regions may result in a different effect on alternative exon selection from binding to a single region (Figure 1). For example, Nova binding to both the regulated exon and its upstream intron increases the probability of exon exclusion. Moreover, it is estimated that ~15% of Nova targets harbor binding sites for the splicing factors Fox-1 and Fox-2, implying combinatory splicing regulation by Nova and Fox (C. Zhang, et al., 2010). Therefore, an intriguing issue is how the relative location of Nova and Fox binding sites dictates splicing regulation (Chen & Manley, 2009; Licatalosi & Darnell, 2010).
Previous studies have also revealed how Nova proteins may modulate the activity of the spliceosome. For example, Nova binding to exons may interfere with U1 snRNP binding to the 5' splice site, thereby inhibiting splicing (Dredge, et al., 2005). When Nova binds to the downstream intron of a regulated exon, it may facilitate spliceosome assembly and promote exon inclusion (Dredge, et al., 2005). As described above, Nova and Fox proteins may coregulate alternative splicing of a considerable number of transcripts in a cooperative or antagonistic manner (C. Zhang, et al., 2010). Notably, neuronal depolarization can induce exon 19 exclusion of Fox-1, producing a Fox-1 isoform with higher splicing activity (Lee, et al., 2009). Therefore, under certain circumstances this Fox-1 isoform may function coordinately with Nova to modulate splicing of Fox-1/Nova-coregulated mRNAs. Moreover, the neuron-enriched nPTB can antagonize Nova action to increase inclusion of GlyRα2 exon 3A (Polydorides, et al., 2000). The physical and functional interactions between Nova and other splicing regulatory factors certainly complicate Nova splicing networks, but the detailed mechanisms remain to be investigated.
3.5. Cellular signaling pathways affect Nova expression level and activity
In contrast to the abundant information about Nova-target interactions, we have only rudimentary knowledge of whether Nova’s function can be modulated by cellular signaling pathways. However, several reports have indicated that Nova expression may be regulated at different gene expression levels. It has been shown that the neuronal protein embryonic lethal abnormal visual (nELAV) can increase the stability of the Nova-1 mRNA via binding to its AU-rich elements in the highly conserved 3'-untranslated region (Ratti, et al., 2008; Rossi, et al., 2009). In addition, protein kinase C–induced phosphorylation of nELAV can promote Nova-1 translation (Ratti, et al., 2008). Therefore, nELAV can increase Nova-1 abundance. Moreover, nELAV can modulate the splicing activity of Nova-1 on its target pre-mRNAs (Ratti, et al., 2008). Glucocorticoids can also regulate Nova-1-mediated alternative splicing by downregulating Nova-1 (E. Park, et al., 2009). Moreover, cholinergic stimulation may decrease Nova-2 transcripts but increase Nova-1 transcripts in striatum (Jelen, et al., 2010). Therefore, the expression switch between these two Nova proteins may modify Nova activity in neurons. Finally, it is noteworthy that Nova-1 can autoregulate its exon 4 inclusion by acting as a splicing repressor (Dredge, et al., 2005). Because exon 4 contains multiple phosphorylation sites for serine/threonine kinases, it would be interesting to know whether Nova-1 may modulate its own activity via autoregulation of alternative splicing in response to activation of specific cellular signaling pathways.
3.6. Physiological function and pathological implications of Nova
Early studies of Nova-1 and -2 showed that these proteins have a reciprocal expression pattern in the neocortex and hippocampus in postnatal mouse brain and may have slightly different RNA-binding specificity and/or affinity (Buckanovich & Darnell, 1997; Yang, et al., 1998). Genetic knockout studies then provided further hints to their different physiological roles. Nova-1 knockout mice died 7-10 days after birth owing to a motor deficit caused by apoptotic death of spinal and brainstem neurons, indicating that Nova-1 is an essential gene in mice (Jensen, et al., 2000; Yang, et al., 1998). Nova-2 null mice died in the second postnatal week, whereas double Nova knockout caused perinatal death (Ruggiu, et al., 2009; Ule, et al., 2006). Microarray analysis revealed distinct splicing defects for Nova-1 vs. Nova-2 knockout mice (Ule, et al., 2005b; C. Zhang, et al., 2010). These results indicate that these two Nova genes have non-redundant physiological functions.
Identified targets of Nova have implicated a role for Nova in synaptic plasticity. As predicted, long-term potentiation induced by GABAB receptor-mediated slow inhibitory postsynaptic current in hippocampal neurons is abolished in Nova-2 knockout mice (Huang, et al., 2005). Moreover, a recent report showed a migration deficiency in cortical and Purkinje neurons in Nova-2 null mice (Yano, et al., 2010). These observations are consistent with the role of Nova-2 in alternative splicing regulation of GABA receptor subunits and of disabled-1, a regulatory factor of the reelin signaling pathway essential for cell positioning during neurogenesis. Therefore, Nova-2 can regulate neuronal migration and synaptic plasticity via its control of alternative splicing.
Certain Nova targets have been implicated in genetic disorders. For example, reelin-disabled-1 signaling may be associated with epilepsy, schizophrenia, and autism (Frotscher, 2010; Pardo & Eberhart, 2007). Interestingly, Fox-1, a functional partner of the Nova proteins, has been implicated in autism (Martin, et al., 2007; Smith & Sadee, 2011). Indeed, the genes coregulated by Nova and Fox appear to be more frequently associated with autism (C. Zhang, et al., 2010). Therefore, aberrant regulation of Nova proteins may contribute to autism.
4. PTB and nPTB
4.1. PTB/nPTB proteins
PTB is a ubiquitously expressed RNA-binding protein containing four RNA recognition motifs with high affinity for CU-rich sequences (Xue, et al., 2009). nPTB is predominant in neurons although also present in other tissues and is remarkably similar to PTB in domain structure and RNA-binding specificity (Spellman, et al., 2007). Both PTB and nPTB primarily function as splicing regulators, and PTB can also regulate translation of specific mRNAs and internal ribosome entry site-mediated translation (Mitchell, et al., 2001; Sawicka, et al., 2008). PTB localizes primarily to the nucleus but can shuttle between the nucleus and cytoplasm (Michael, et al., 1995). Protein kinase A-mediated phosphorylation of PTB can cause its accumulation in the cytoplasm, thereby promoting its cytoplasmic functions such as translation control and RNA transport (Ma, et al., 2007; Xie, et al., 2003).
4.2. Mechanisms of PTB/nPTB-controlled alternative spicing
Multiple mechanisms underlie PTB/nPTB-induced splicing regulation. In general, PTB and nPTB function as splicing inhibitors. Because CU-rich sequences frequently appear in the 3' end of most constitutive introns, binding of PTB to this region interferes with recognition of the 3' splice site by the essential splicing factor, U2AF, thus preventing spliceosome assembly (Sharma, et al., 2005). Moreover, CU-rich elements are also located in other discrete intronic regions surrounding alternative exons. PTB can loop out a regulated exon via binding to both its upstream and downstream intronic CU-rich sequences and forming homomultimers, which thus drives exon exclusion (Lamichhane, et al., 2010). Consistently, a recent genome-wide mapping of PTB-binding sites revealed a position effect for PTB-mediated splicing regulation (Sawicka, et al., 2008) (Figure 2). When PTB binds near an alternative exon, it generally induces exon skipping. However, PTB can also promote exon inclusion when it binds close to a strong constitutive splice site. Besides self-interaction, PTB can also interact with other splicing factors to form complexes that often compete with the splicing machinery, thereby interfering with splicing (Sharma, et al., 2011). A recent report showed that PTB can interact with a pyrimidine-rich loop of U1 snRNA and alter its recognition of the 5' splice site (Coutinho-Mansfield, et al., 2007). nPTB may use similar mechanisms as PTB to suppress exon inclusion. However, nPTB appears to be a weaker splicing suppressor compared with PTB, and nPTB may interact with additional transcripts that are implicated in neuronal activity (Spellman, et al., 2007). Thus, PTB and nPTB have distinct properties in regulating alternative splicing.
4.3. The PTB/nPTB switch during neuronal differentiation
Immunocytochemistry has shown that PTB is detected in neuronal precursor cells as well as non-neuronal lineages of the brain whereas nPTB is specifically expressed in post-mitotic neurons (Boutz, et al., 2007). Therefore, a switch in expression from PTB to nPTB likely occurs during neuronal differentiation. To date, two post-transcriptional mechanisms have been implicated in mutually exclusive expression of PTB and nPTB (Boutz, et al., 2007; Makeyev, et al., 2007). One mechanism involves alternative splicing-coupled nonsense-mediated decay, and the other involves microRNA-mediated translation control. Skipping of exon 11 of PTB and exon 10 of nPTB generates transcripts containing a premature termination codon that subsequently undergo nonsense-mediated decay. PTB is responsible for such exon suppression by binding to highly conserved CU-rich elements flanking the alternative PTB/nPTB exons (Figure 2). Through this activity, PTB may negatively autoregulate its own expression, perhaps to maintain appropriate levels of the protein and restrict the expression of nPTB in non-neuronal cells. In addition, the neuron-specific microRNA miR-124 can directly target to the PTB mRNA and suppresses its translation (Makeyev, et al., 2007). Therefore, PTB expression is down-regulated in neurons, which thus relieves nPTB suppression.
4.4. The PTB/nPTB switch reprograms specific splicing events
Although nPTB and PTB have overlapping function, their different spatial and timely expression patterns in neurons suggest that they have diverse physiological functions in splicing regulation. Indeed, a recent report showed that ~25% of neuron-specific alternative splicing events may result from a decrease of PTB and increase of nPTB during neuronal differentiation (Boutz, et al., 2007). The possible distinct target specificity of PTB and nPTB may be important for establishing unique and neuron-specific splicing programs during neuronal differentiation. Therefore, the PTB/nPTB switch may have evolved as a post-transcriptional mechanism to fine tune the existing program and alter the transcriptome to promote cell differentiation.
As described above, Nova-1 and Nova-2, although having highly similar sequences, contribute to neuron-specific splicing in different types of neurons (C. Zhang, et al., 2010). Given that Nova-1 can drive its own exon 4 skipping, the Nova-1/Nova-2 reciprocal expression may in part proceed through a negative feedback control mechanism similar to that used by PTB/nPTB (Coutinho-Mansfield, et al., 2007; Dredge, et al., 2005). Therefore, the switch between two highly similar but still distinct splicing factors may provide a potent and rapid means to adjust cellular function in a specific environment.
5. SMN
5.1. SMN genes and expression
Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by degeneration of lower motor neurons in the spinal cord with subsequent muscle atrophy (Pearn, 1978). SMA is caused by deletions or mutations of the survival of motor neuron 1 (SMN1) gene (Lefebvre, et al., 1995). In human, the SMN2 gene is almost identical to SMN1 but contains a C to T transition at position 6 in exon 7. This nucleotide change induces SMN2 exon 7 skipping during splicing and results in an unstable truncated SMN protein (Cho & Dreyfuss, 2010). Therefore, SMN2 fails to produce a sufficient amount of functional SMN protein to compensate for the loss of SMN1 (Lorson, et al., 1999; Monani, et al., 1999). Multiple factors have been proposed to regulate exon 7 inclusion/exclusion of the SMN transcripts. In principle, SMN1 exon 7 harbors a splicing enhancer for the splicing activator SF2/ASF, which promotes exon 7 inclusion in the SMN1 transcript, whereas the C to U change in SMN2 pre-mRNA disrupts the binding of SF2/ASF but creates a recognition site for the suppressor hnRNP A1 that excludes exon 7 (Cartegni, et al., 2006; Cartegni & Krainer, 2002; Kashima & Manley, 2003; Kashima, et al., 2007). Besides, other SMN regulators may function via direct binding to exon 7 or even to intronic elements or through a protein complex to modulate exon 7 selection (Doktor, et al., 2011; Nlend Nlend, et al., 2010; Pedrotti & Sette, 2010). SMN splicing regulation has been reviewed elsewhere; this section thus focuses on SMN function in pre-mRNA splicing and regulation.
5.2. SMN and its cellular localization
SMN expression is not restricted to neurons, and in fact it is expressed in all cell types Unlike Nova and PTB, SMN lacks a typical RNA-binding domain but contains a Tudor domain that mediates its interaction with the Sm proteins of spliceosomal snRNPs. Indeed, SMN participates in snRNP biogenesis, which is an important housekeeping function, and also in splicing, transcription, and neuronal mRNA trafficking (Burghes & Beattie, 2009; Coady & Lorson, 2011) (Figure 3). In the nucleus, SMN is particularly concentrated in discrete nuclear bodies that are very close to Cajal bodies (Carvalho, et al., 1999; Young, et al., 2000). This nuclear localization pattern suggests a role for SMN in nuclear snRNP maturation and regeneration. In neurons, SMN forms cytoplasmic granules in neurites and growth cones and participates in active bidirectional transport of mRNAs (Fallini, et al., 2011; Todd, et al., 2010; H. Zhang, et al., 2006). SMN deficiency disrupts Cajal bodies and impairs mRNA trafficking in motor neuron axons (Girard, et al., 2006; Rossoll, et al., 2003; Shpargel & Matera, 2005 indicating that the diverse subcellular distribution of SMN is functionally important. Moreover, a recent observation that SMN associates and colocalizes with the α subunit of “coatomer”, a protein coat for vesicles that mediate intracellular transport, indicates a role for Golgi-associated COPI vesicles in SMN transport (Peter, et al., 2011).
5.3. SMN in snRNP biogenesis
The role of SMN in snRNP biogenesis has been well characterized. Assembly of the heptameric Sm cores with each spliceosomal snRNA occurs in a highly ordered manner (Burghes & Beattie, 2009; Cauchi, 2010; Coady & Lorson, 2011). Initially, the chaperon factor pICln brings methylated Sm protein subcomplexes to the SMN complex, which is composed of SMN, Gemin2-8, and unr-interacting proteins. The SMN complex facilitates the arrangement of the Sm proteins on a single-stranded region of snRNA to form a ring-shaped structure of the snRNP. An initial report showed that ~80% depletion of SMN by RNA interference in cultured mammalian cells had no significant loss-of-function effect on snRNP assembly (Girard, et al., 2006). Perhaps excess SMN complex exists in cells to maintain normal levels of the basal splicing machinery. However, further reduction of SMN differentially impaired snRNP assembly (Gabanella, et al., 2007; Workman, et al., 2009; Z. Zhang, et al., 2008). In particular, the levels of several U12-type spliceosomal snRNAs decreased more significantly in SMA mice, and formation of the U12-type tri-snRNPs was also impeded in lymphoblasts derived from SMA patients (Gabanella, et al., 2007; Workman, et al., 2009; Z. Zhang, et al., 2008). The latter observation is also in accordance with the assumption that SMN is possibly involved in tri-snRNP assembly in Cajal bodies (Carvalho, et al., 1999; Novotny, et al., 2011; Young, et al., 2000). Although direct evidence for defective snRNP assembly or reduced snRNP levels in SMA pathogenesis is lacking, one hint has been provided by the observation that knockdown of SMN or other snRNP assembly factors in zebrafish causes motor axon defects (Winkler, et al., 2005).
5.4. SMN in pre-mRNA splicing
It is clear that SMN has an essential function for snRNP biogenesis, and possibly that insufficient SMN causes various degrees of snRNP assembly defects. However, whether loss of SMN affects splicing of a wide range or a specific set of transcripts and whether the effect of SMN in splicing, if any, indeed results from impaired snRNP assembly have just begun to be investigated.
Exon array analysis has shown that splicing of numerous transcripts is affected in various tissues of late-symptomatic SMA mice (Z. Zhang, et al., 2008). It is unclear whether such a widespread splicing defect is caused by reduced levels of SMN. It is suspected that the decrease in SMN level may affect splicing of specific transcripts in motor neurons that are most vulnerable to degeneration in SMA (Briese, et al., 2005; Liu, et al., 2010; Monani, 2005). A recent report showed that the tri-snRNP of the U12-type splicing machinery is most affected in SMA patients and, consistently, the splicing of a subgroup of U12-type introns is affected (Boulisfane, et al., 2011). Because U12-type introns are present in a number of genes involved in cytoskeletal organization, defects in their excision may impair motor neuron function. Finally, the error rate of exon inclusion/skipping is higher in fibroblasts of SMA patients, perhaps owing to poor recognition of the splice sites by a low abundance of functional snRNPs (Fox-Walsh & Hertel, 2009).
5.5. How does SMN deficiency cause SMA pathogenesis
To date, two plausible possibilities have been raised to explain how SMN deficiency causes specific neurological defects of motor neurons. First, as discussed above, inefficient snRNP assembly may affect the splicing of a specific set of transcripts that are critical to motor neuron functions. However, issues such as which transcripts are most sensitive to SMN deficiency and whether their splicing defects lead to SMA pathogenesis remain to be investigated. In addition, it has been shown that SMN forms RNA granules with other RNA-binding proteins such as hnRNP R to deliver β-actin mRNA in motor axons (Glinka, et al., 2010; Rossoll, et al., 2003). A recent report showed that clustering of Cav2.2 calcium channels is impaired in axonal growth cones of SMA animals, and such a defect can be restored by rescue of SMN expression (Jablonka, et al., 2007). It is possible that SMN plays a role in actin filament formation via β-actin mRNA trafficking, and such an activity of SMN is critical for motor neuron functions.
SMA patients and animal models show a variable extent of defects in neuromuscular junction functions, axonal arborization, synaptic transport, and neurodevelopment. Such complexity may result from different residual levels of SMN in different systems as well as multiple cellular functions and interacting partners of SMN (Boyer, et al., 2010; Burghes & Beattie, 2009; Cauchi, 2010; Wu, et al., 2011). Nevertheless, restoration of SMN levels or function is certainly a primary therapeutic strategy for SMA treatment (Kolb & Kissel, 2011). For example, activation of SMN2 transcription and restoration of SMN2 splicing ameliorate symptoms of SMA mice and thus provide promise for future SMA treatment.
6. Conclusions
Our understanding of splicing regulation mechanisms and splicing regulatory networks has been advanced substantially by recent studies using gene inactivation techniques and genome-wide experimental and computational examination of alternative splicing events. In the past decade, CLIP in conjunction with various types of mRNA identification systems has been used extensively for
Our understanding of the physiological consequences of alternative splicing still largely relies on genetic approaches. For example, knockout of splicing factors in animals in combination of mRNA isoform comparison can facilitate the identification of their
Acknowledgments
We acknowledge support from intramural funds of the Institute of Biomedical Sciences, Academia Sinica, and the Academia Sinica Investigator Award to W.-Y. Tarn.
References
- 1.
Allen S. E. Darnell R. B. Lipscombe D. 2010 The neuronal splicing factor Nova controls alternative splicing in N-type and P-type CaV2 calcium channels. ,4 6 Nov-Dec, 201483 489 - 2.
Ares M. Jr 2007 Sing the genome electric: excited cells adjust their splicing. ,5 2 Feb, 200e55 - 3.
Boulisfane N. Choleza M. Rage F. Neel H. Soret J. Bordonne R. 2011 Impaired minor tri-snRNP assembly generates differential splicing defects of U12-type introns in lymphoblasts derived from a type I SMA patient. ,20 4 Feb 15, 201641 648 - 4.
Boutz P. L. Stoilov P. Li Q. Lin C. H. Chawla G. Ostrow K. Shiue L. Ares M. Jr Black D. L. 2007 A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. ,21 13 Jul 1, 2001636 1652 - 5.
Boyer J. G. Bowerman M. Kothary R. 2010 The many faces of SMN: deciphering the function critical to spinal muscular atrophy pathogesis. ,5 6 873 890 - 6.
Briese M. Esmaeili B. Sattelle D. B. 2005 Is spinal muscular atrophy the result of defects in motor neuron processes? ,27 9 Sep, 200946 957 - 7.
Brooks A. N. Yang L. Duff M. O. Hansen K. D. Park J. W. Dudoit S. Brenner S. E. Graveley B. R. 2011 Conservation of an RNA regulatory map between Drosophila and mammals. ,21 2 Feb, 201193 202 - 8.
Buckanovich R. J. Darnell R. B. 1997 The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo. ,17 6 Jun, 1993194 3201 - 9.
Buckanovich R. J. Posner J. B. Darnell R. B. 1993 Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. ,11 4 Oct, 199657 672 - 10.
Buckanovich R. J. Yang Y. Y. Darnell R. B. 1996 The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. ,16 3 Feb 1, 1991114 1122 - 11.
Burghes A. H. Beattie C. E. 2009 Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? ,10 8 Aug, 200597 609 - 12.
Calarco J. A. Superina S. O’Hanlon D. Gabut M. Raj B. Pan Q. Skalska U. Clarke L. Gelinas D. van der Kooy D. Zhen M. Ciruna B. Blencowe B. J. 2009 Regulation of vertebrate nervous system alternative splicing and development by an SR-related protein. ,138 5 Sep 4, 200898 910 - 13.
Calarco J. A. Zhen M. Blencowe B. J. 2011 Networking in a global world: Establishing functional connections between neural splicing regulators and their target transcripts. ,17 5 May, 201775 791 - 14.
Cartegni L. Hastings M. L. Calarco J. A. de Stanchina E. Krainer A. R. 2006 Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. ,78 1 Jan, 20063 77 - 15.
Cartegni L. Krainer A. R. 2002 Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. ,30 4 Apr, 200377 384 - 16.
Carvalho T. Almeida F. Calapez A. Lafarga M. Berciano M. T. Carmo-Fonseca M. 1999 The spinal muscular atrophy disease gene product, SMN: A link between snRNP biogenesis and the Cajal (coiled) body. ,147 4 Nov 15, 199715 728 - 17.
Cauchi R. J. 2010 SMN and Gemins: ‘we are family’... or are we?: insights into the partnership between Gemins and the spinal muscular atrophy disease protein SMN. ,32 12 Dec, 2011077 1089 - 18.
Chen M. Manley J. L. 2009 Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. ,10 11 Nov, 200741 754 - 19.
Chmiel N. H. Rio D. C. Doudna J. A. 2006 Distinct contributions of KH domains to substrate binding affinity of Drosophila P-element somatic inhibitor protein. ,12 2 Feb, 200283 291 - 20.
Cho S. Dreyfuss G. 2010 A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. ,24 5 Mar 1, 201438 442 - 21.
Coady T. H. Lorson C. L. 2011 SMN in spinal muscular atrophy and snRNP biogenesis. , 201 pp. n/a-n/a - 22.
Coutinho-Mansfield G. C. Xue Y. Zhang Y. Fu X. D. 2007 PTB/nPTB switch: a post-transcriptional mechanism for programming neuronal differentiation. ,21 13 Jul 1, 2001573 1577 - 23.
Darnell R. B. 2010 HITS-CLIP: panoramic views of protein-RNA regulation in living cells. ,1 266 286 - 24.
Darnell R. B. 2011 RNA regulation in Neurodegeneration and Cancer, In: Curran, T. & Christen, Y.,103 111 Springer Berlin Heidelberg, 978-3-642-16602-0, - 25.
Darnell R. B. Posner J. B. 2003 Paraneoplastic syndromes involving the nervous system. ,349 16 Oct 16, 2001543 1554 - 26.
Doktor T. K. Schroeder L. D. Vested A. Palmfeldt J. Andersen H. S. Gregersen N. Andresen B. S. 2011 SMN2 exon 7 splicing is inhibited by binding of hnRNP A1 to a common ESS motif that spans the 3’ splice site. ,32 2 Feb, 201220 230 - 27.
Dredge B. K. Darnell R. B. 2003 Nova regulates GABA(A) receptor gamma2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer. ,23 13 Jul, 2004687 4700 - 28.
Dredge B. K. Stefani G. Engelhard C. C. Darnell R. B. 2005 Nova autoregulation reveals dual functions in neuronal splicing. ,24 8 Apr 20, 2001608 1620 - 29.
Fallini C. Zhang H. Su Y. Silani V. Singer R. H. Rossoll W. Bassell G. J. 2011 The Survival of Motor Neuron (SMN) Protein Interacts with the mRNA-Binding Protein HuD and Regulates Localization of Poly(A) mRNA in Primary Motor Neuron Axons. ,31 10 Mar 9, 2013914 3925 - 30.
Fox-Walsh K. L. Hertel K. J. 2009 Splice-site pairing is an intrinsically high fidelity process. ,106 6 Feb 10, 2001766 1771 - 31.
Frotscher M. 2010 Role for Reelin in stabilizing cortical architecture. ,33 9 Sep, 201407 414 - 32.
Gabanella F. Butchbach M. E. Saieva L. Carissimi C. Burghes A. H. Pellizzoni L. 2007 Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. ,2 9 e921 - 33.
Girard C. Neel H. Bertrand E. Bordonne R. 2006 Depletion of SMN by RNA interference in HeLa cells induces defects in Cajal body formation. ,34 10 2925 2932 - 34.
Glinka M. Herrmann T. Funk N. Havlicek S. Rossoll W. Winkler C. Sendtner M. 2010 The heterogeneous nuclear ribonucleoprotein-R is necessary for axonal beta-actin mRNA translocation in spinal motor neurons. ,19 10 May 15, 2011951 1966 - 35.
Grabowski P. 2011 Alternative splicing takes shape during neuronal development. , (Apr 19, 201 pp. - 36.
Hattori D. Millard S. S. Wojtowicz W. M. Zipursky S. L. 2008 Dscam-mediated cell recognition regulates neural circuit formation. ,24 597 620 - 37.
Huang C. S. Shi S. H. Ule J. Ruggiu M. Barker L. A. Darnell R. B. Jan Y. N. Jan L. Y. 2005 Common molecular pathways mediate long-term potentiation of synaptic excitation and slow synaptic inhibition. ,123 1 Oct 7, 200105 118 - 38.
Irimia M. Denuc A. Burguera D. Somorjai I. Martin-Duran J. M. Genikhovich G. Jimenez-Delgado S. Technau U. Roy S. W. Marfany G. Garcia-Fernandez J. 2011 Stepwise assembly of the Nova-regulated alternative splicing network in the vertebrate brain. ,108 13 Mar 29, 2015319 5324 - 39.
Isken O. Maquat L. E. 2007 Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function. ,21 15 Aug 1, 2001833 1856 - 40.
Jablonka S. Beck M. Lechner B. D. Mayer C. Sendtner M. 2007 Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy. ,179 1 Oct 8, 200139 149 - 41.
Jelen N. Ule J. Zivin M. 2010 Cholinergic regulation of striatal Nova mRNAs. ,169 2 Aug 25, 201619 627 - 42.
Jelen N. Ule J. Zivin M. Darnell R. B. 2007 Evolution of Nova-dependent splicing regulation in the brain. ,3 10 Oct, 2001838 1847 - 43.
Jensen K. B. Dredge B. K. Stefani G. Zhong R. Buckanovich R. J. Okano H. J. Yang Y. Y. Darnell R. B. 2000 Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. ,25 2 Feb, 200359 371 - 44.
Kashima T. Manley J. L. 2003 A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. ,34 4 Aug, 200460 463 - 45.
Kashima T. Rao N. David C. J. Manley J. L. 2007 hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. ,16 24 Dec 15, 2003149 3159 - 46.
Keren H. Lev-Maor G. Ast G. 2010 Alternative splicing and evolution: diversification, exon definition and function. ,11 5 May, 201345 355 - 47.
Khabar K. S. 2010 Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. ,67 17 Sep, 2012937 2955 - 48.
Kolb S. J. Kissel J. T. 2011 Spinal Muscular Atrophy: A Timely Review. , (Apr 11, 201 pp. - 49.
Konig J. Zarnack K. Rot G. Curk T. Kayikci M. Zupan B. Turner D. J. Luscombe N. M. Ule J. 2010 iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. ,17 7 Jul, 201909 915 - 50.
Lamichhane R. Daubner G. M. Thomas-Crusells J. Auweter S. D. Manatschal C. Austin K. S. Valniuk O. Allain F. H. Rueda D. 2010 RNA looping by PTB: Evidence using FRET and NMR spectroscopy for a role in splicing repression. ,107 9 Mar 2, 2014105 4110 - 51.
Lee J. A. Tang Z. Z. Black D. L. 2009 An inducible change in Fox-1/A2BP1 splicing modulates the alternative splicing of downstream neuronal target exons. ,23 19 Oct 1, 2002284 2293 - 52.
Lefebvre S. Burglen L. Reboullet S. Clermont O. Burlet P. Viollet L. Benichou B. Cruaud C. Millasseau P. Zeviani M. et al. 1995 Identification and characterization of a spinal muscular atrophy-determining gene. ,80 1 Jan 13, 199155 165 - 53.
Lewis H. A. Musunuru K. Jensen K. B. Edo C. Chen H. Darnell R. B. Burley S. K. 2000 Sequence-specific RNA binding by a Nova KH domain: implications for paraneoplastic disease and the fragile X syndrome. ,100 3 Feb 4, 200323 332 - 54.
Li Q. Lee J. A. Black D. L. 2007 Neuronal regulation of alternative pre-mRNA splicing. ,8 11 Nov, 200819 831 - 55.
Licatalosi D. D. Darnell R. B. 2010 RNA processing and its regulation: global insights into biological networks. ,11 1 Jan, 20175 87 - 56.
Licatalosi D. D. Mele A. Fak J. J. Ule J. Kayikci M. Chi S. W. Clark T. A. Schweitzer A. C. Blume J. E. Wang X. Darnell J. C. Darnell R. B. 2008 HITS-CLIP yields genome-wide insights into brain alternative RNA processing. ,456 7221 Nov 27, 200464 469 - 57.
Liu H. Shafey D. Moores J. N. Kothary R. 2010 Neurodevelopmental consequences of Smn depletion in a mouse model of spinal muscular atrophy. ,88 1 Jan, 201111 122 - 58.
Lorson C. L. Hahnen E. Androphy E. J. Wirth B. 1999 A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. ,96 11 May 25, 1996307 6311 - 59.
Lorson C. L. Rindt H. Shababi M. 2010 Spinal muscular atrophy: mechanisms and therapeutic strategies. ,19 R1 Apr 15, 201R111 R118 - 60.
Lukong K. E. Chang K. W. Khandjian E. W. Richard S. 2008 RNA-binding proteins in human genetic disease. ,24 8 Aug, 200416 425 - 61.
Ma S. Liu G. Sun Y. Xie J. 2007 Relocalization of the polypyrimidine tract-binding protein during PKA-induced neurite growth. ,1773 6 Jun, 200912 923 - 62.
Makeyev E. V. Zhang J. Carrasco M. A. Maniatis T. 2007 The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. ,27 3 Aug 3, 200435 448 - 63.
Martin C. L. Duvall J. A. Ilkin Y. Simon J. S. Arreaza M. G. Wilkes K. Alvarez-Retuerto A. Whichello A. Powell C. M. Rao K. Cook E. Geschwind D. H. 2007 Cytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for autism. ,144B 7 Oct 5, 200869 876 - 64.
Mc Glincy N. J. Smith C. W. 2008 Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? ,33 8 Aug, 200385 393 - 65.
Michael W. M. Siomi H. Choi M. Pinol-Roma S. Nakielny S. Liu Q. Dreyfuss G. 1995 Signal sequences that target nuclear import and nuclear export of pre-mRNA-binding proteins. ,60 663 668 - 66.
Mitchell S. A. Brown E. C. Coldwell M. J. Jackson R. J. Willis A. E. 2001 Protein factor requirements of the Apaf-1 internal ribosome entry segment: roles of polypyrimidine tract binding protein and upstream of N-ras. ,21 10 May, 2003364 3374 - 67.
Monani U. R. 2005 Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease. ,48 6 Dec 22, 200885 896 - 68.
Monani U. R. Lorson C. L. Parsons D. W. Prior T. W. Androphy E. J. Burghes A. H. Mc Pherson J. D. 1999 A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. ,8 7 Jul, 1991177 1183 - 69.
Moore M. J. Proudfoot N. J. 2009 Pre-mRNA processing reaches back to transcription and ahead to translation. ,136 4 Feb 20, 200688 700 - 70.
Moroy T. Heyd F. 2007 The impact of alternative splicing in vivo: mouse models show the way. ,13 8 Aug, 2001155 1171 - 71.
Musunuru K. Darnell R. B. 2004 Determination and augmentation of RNA sequence specificity of the Nova K-homology domains. ,32 16 4852 4861 - 72.
Nilsen T. W. Graveley B. R. 2010 Expansion of the eukaryotic proteome by alternative splicing. ,463 7280 Jan 28, 201457 463 - 73.
Nlend Nlend. R. Meyer K. Schumperli D. 2010 Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy. ,7 4 Nov 19, 201430 440 - 74.
Novotny I. Blazikova M. Stanek D. Herman P. Malinsky J. 2011 In vivo kinetics of U4/U6.U5 tri-snRNP formation in Cajal bodies. ,22 4 Feb 15, 201513 523 - 75.
Pan Q. Shai O. Lee L. J. Frey B. J. Blencowe B. J. 2008 Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. ,40 12 Dec, 2001413 1415 - 76.
Pardo C. A. Eberhart C. G. 2007 The neurobiology of autism. ,17 4 Oct, 200434 447 - 77.
Park E. Lee M. S. Baik S. M. Cho E. B. Son G. H. Seong J. Y. Lee K. H. Kim K. 2009 Nova-1 mediates glucocorticoid-induced inhibition of pre-mRNA splicing of gonadotropin-releasing hormone transcripts. ,284 19 May 8, 20012792 12800 - 78.
Park G. H. Kariya S. Monani U. R. 2010 Spinal muscular atrophy: new and emerging insights from model mice. ,10 2 Mar, 201108 117 - 79.
Park J. W. Graveley B. R. 2007 Complex alternative splicing. ,623 50 63 - 80.
Pearn J. 1978 Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. ,15 6 Dec, 197409 413 - 81.
Pedrotti S. Sette C. 2010 Spinal muscular atrophy: a new player joins the battle for SMN2 exon 7 splicing. ,9 19 Oct 1, 2013874 3879 - 82.
Peter C. J. Evans M. Thayanithy V. Taniguchi-Ishigaki N. Bach I. Kolpak A. Bassell G. J. Rossoll W. Lorson C. L. Bao Z. Z. Androphy E. J. 2011 The COPI vesicle complex binds and moves with survival motor neuron within axons. ,20 9 May 1, 2011701 1711 - 83.
Polydorides A. D. Okano H. J. Yang Y. Y. Stefani G. Darnell R. B. 2000 A brain-enriched polypyrimidine tract-binding protein antagonizes the ability of Nova to regulate neuron-specific alternative splicing. ,97 12 Jun 6, 2006350 6355 - 84.
Racca C. Gardiol A. Eom T. Ule J. Triller A. Darnell R. B. 2010 The Neuronal Splicing Factor Nova Co-Localizes with Target RNAs in the Dendrite. ,4 5 - 85.
Ratti A. Fallini C. Colombrita C. Pascale A. Laforenza U. Quattrone A. Silani V. 2008 Post-transcriptional regulation of neuro-oncological ventral antigen 1 by the neuronal RNA-binding proteins ELAV. ,283 12 Mar 21, 2007531 7541 - 86.
Rossi D. Amadio M. Carnevale Baraglia. A. Azzolina O. Ratti A. Govoni S. Pascale A. Collina S. 2009 Discovery of small peptides derived from embryonic lethal abnormal vision proteins structure showing RNA-stabilizing properties. ,52 16 Aug 27, 2005017 5019 - 87.
Rossoll W. Jablonka S. Andreassi C. Kroning A. K. Karle K. Monani U. R. Sendtner M. 2003 Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. ,163 4 Nov 24, 200801 812 - 88.
Ruggiu M. Herbst R. Kim N. Jevsek M. Fak J. J. Mann M. A. Fischbach G. Burden S. J. Darnell R. B. 2009 Rescuing Z+ agrin splicing in Nova null mice restores synapse formation and unmasks a physiologic defect in motor neuron firing. ,106 9 Mar 3, 2003513 3518 - 89.
Saltzman A. L. Pan Q. Blencowe B. J. 2011 Regulation of alternative splicing by the core spliceosomal machinery. ,25 4 Feb 15, 201373 384 - 90.
Sawicka K. Bushell M. Spriggs K. A. Willis A. E. 2008 Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein. ,36 No.Pt 4, (Aug, 200641 647 - 91.
Seshaiah P. Miller B. Myat M. M. Andrew D. J. 2001 pasilla, the Drosophila homologue of the human Nova-1 and Nova-2 proteins, is required for normal secretion in the salivary gland. ,239 2 Nov 15, 200309 322 - 92.
Sharma S. Falick A. M. Black D. L. 2005 Polypyrimidine tract binding protein blocks the 5’ splice site-dependent assembly of U2AF and the prespliceosomal E complex. ,19 4 Aug 19, 200485 496 - 93.
Sharma S. Maris C. Allain F. H. Black D. L. 2011 U1 snRNA directly interacts with polypyrimidine tract-binding protein during splicing repression. ,41 5 Mar 4, 201579 588 - 94.
Shpargel K. B. Matera A. G. 2005 Gemin proteins are required for efficient assembly of Sm-class ribonucleoproteins. ,102 48 Nov 29, 20017372 17377 - 95.
Smith R. M. Sadee W. 2011 Synaptic signaling and aberrant RNA splicing in autism spectrum disorders. ,3 1 - 96.
Spellman R. Llorian M. Smith C. W. 2007 Crossregulation and functional redundancy between the splicing regulator PTB and its paralogs nPTB and ROD1. ,27 3 Aug 3, 200420 434 - 97.
Tang Z. Z. Sharma S. Zheng S. Chawla G. Nikolic J. Black D. L. 2011 Regulation of the Mutually Exclusive Exons 8a and 8 in the CaV1.2 Calcium Channel Transcript by Polypyrimidine Tract-binding Protein. ,286 12 Mar 25, 20110007 10016 - 98.
Thiele A. Nagamine Y. Hauschildt S. Clevers H. 2006 AU-rich elements and alternative splicing in the beta-catenin 3’UTR can influence the human beta-catenin mRNA stability. ,312 12 Jul 15, 2002367 2378 - 99.
Todd A. G. Morse R. Shaw D. J. Mc Ginley S. Stebbings H. Young P. J. 2010 SMN, Gemin2 and Gemin3 associate with beta-actin mRNA in the cytoplasm of neuronal cells in vitro. ,401 5 Sep 3, 201681 689 - 100.
Ule J. Jensen K. Mele A. Darnell R. B. 2005a CLIP: a method for identifying protein-RNA interaction sites in living cells. ,37 4 Dec, 2005a),376 386 - 101.
Ule J. Jensen K. B. Ruggiu M. Mele A. Ule A. Darnell R. B. 2003 CLIP identifies Nova-regulated RNA networks in the brain. ,302 5648 Nov 14, 2001212 1215 - 102.
Ule J. Stefani G. Mele A. Ruggiu M. Wang X. Taneri B. Gaasterland T. Blencowe B. J. Darnell R. B. 2006 An RNA map predicting Nova-dependent splicing regulation. ,444 7119 Nov 30, 200580 586 - 103.
Ule J. Ule A. Spencer J. Williams A. Hu J. S. Cline M. Wang H. Clark T. Fraser C. Ruggiu M. Zeeberg B. R. Kane D. Weinstein J. N. Blume J. Darnell R. B. 2005b Nova regulates brain-specific splicing to shape the synapse. ,37 8 Aug, 2005b),844 852 - 104.
Valenzuela D. M. Murphy A. J. Frendewey D. Gale N. W. Economides A. N. Auerbach W. Poueymirou W. T. Adams N. C. Rojas J. Yasenchak J. Chernomorsky R. Boucher M. Elsasser A. L. Esau L. Zheng J. Griffiths J. A. Wang X. Su H. Xue Y. Dominguez M. G. Noguera I. Torres R. Macdonald L. E. Stewart A. F. De Chiara T. M. Yancopoulos G. D. 2003 High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. ,21 6 Jun, 200652 659 - 105.
Valverde R. Edwards L. Regan L. 2008 Structure and function of KH domains. ,275 11 Jun, 2002712 2726 - 106.
Wang E. T. Sandberg R. Luo S. Khrebtukova I. Zhang L. Mayr C. Kingsmore S. F. Schroth G. P. Burge C. B. 2008 Alternative isoform regulation in human tissue transcriptomes. ,456 7221 Nov 27, 200470 476 - 107.
Wang Z. Burge C. B. 2008 Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. ,14 5 May, 200802 813 - 108.
Winkler C. Eggert C. Gradl D. Meister G. Giegerich M. Wedlich D. Laggerbauer B. Fischer U. 2005 Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. ,19 19 Oct 1, 2002320 2330 - 109.
Witten J. T. Ule J. 2011 Understanding splicing regulation through RNA splicing maps. ,27 3 Mar, 20189 97 - 110.
Workman E. Saieva L. Carrel T. L. Crawford T. O. Liu D. Lutz C. Beattie C. E. Pellizzoni L. Burghes A. H. 2009 A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice. ,18 12 Jun 15, 2002215 2229 - 111.
Wu C. Y. Whye D. Glazewski L. Choe L. Kerr D. Lee K. H. Mason R. W. Wang W. 2011 Proteomic assessment of a cell model of spinal muscular atrophy. ,12 25 - 112.
Xie J. Lee J. A. Kress T. L. Mowry K. L. Black D. L. 2003 Protein kinase A phosphorylation modulates transport of the polypyrimidine tract-binding protein. ,100 15 Jul 22, 2008776 8781 - 113.
Xue Y. Zhou Y. Wu T. Zhu T. Ji X. Kwon Y. S. Zhang C. Yeo G. Black D. L. Sun H. Fu X. D. Zhang Y. 2009 Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. ,36 6 Dec 25, 200996 1006 - 114.
Yang Y. Y. Yin G. L. Darnell R. B. 1998 The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. ,95 22 Oct 27, 19913254 13259 - 115.
Yano M. Hayakawa-Yano Y. Mele A. Darnell R. B. 2010 Nova2 regulates neuronal migration through an RNA switch in disabled-1 signaling. ,66 6 Jun 24, 201848 858 - 116.
Yeo G. W. Coufal N. G. Liang T. Y. Peng G. E. Fu X. D. Gage F. H. 2009 An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells. ,16 2 Feb, 200130 137 - 117.
Young P. J. Le T. T. thi Man. N. Burghes A. H. Morris G. E. 2000 The relationship between SMN, the spinal muscular atrophy protein, and nuclear coiled bodies in differentiated tissues and cultured cells. ,256 2 May 1, 200365 374 - 118.
Zhang C. Frias M. A. Mele A. Ruggiu M. Eom T. Marney C. B. Wang H. Licatalosi D. D. Fak J. J. Darnell R. B. 2010 Integrative modeling defines the Nova splicing-regulatory network and its combinatorial controls. ,329 5990 Jul 23, 201439 443 - 119.
Zhang H. Xing L. Rossoll W. Wichterle H. Singer R. H. Bassell G. J. 2006 Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons. ,26 33 Aug 16, 2008622 8632 - 120.
Zhang Z. Lotti F. Dittmar K. Younis I. Wan L. Kasim M. Dreyfuss G. 2008 SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. ,133 4 May 16, 200585 600